NCT07196592 · NOT YET RECRUITING

Development of a Novel Multidimensional Therapeutic Intervention Protocol for MCI

This trial is testing a non-drug brain stimulation approach for people with mild cognitive impairment linked to early Alzheimer's. It combines transcranial alternating current stimulation (gentle electrical pulses targeting specific brain rhythms) with a multisensory virtual reality experience involving smell, sound, and vision. Researchers want to know whether this combination improves cognition and brain function. This is a Phase NA large-scale cohort study — it is exploratory and not yet proven or approved.

Eligibility criteria

Inclusion Criteria:
Baseline screening inclusion criteria: a) Age ≤ 65 years and ≤ 85 years; b) Education duration ≥ 1 year; c) Normal cognitive function at enrollment: MMSE total score: non-illiterate (primary school or below) ≥ 20 points, primary school or above ≥ 24 points; d) Corrected vision and hearing are basically normal, and able to complete cognitive assessment.
Exclusion Criteria:
Baseline screening exclusion criteria: a) Neurological/psychiatric disorders affecting cognitive function: depression, schizophrenia, mental retardation, Parkinson's disease, etc.; b) Severe physical illnesses: cardiovascular disease, cerebrovascular disease, tumors, diabetes, kidney disease, and hypertension stage III or above; c) Autoimmune inflammatory diseases such as rheumatoid arthritis, lupus erythematosus, osteoarthritis, and multiple sclerosis.

The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.

Eligibility criteria as of 2025-09-29

View full record on ClinicalTrials.gov

All APOE4 clinical trials